Pigs possess six IgG subclasses, though recent studies identify eight engineered variants (IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgG4, IgG5b, IgG5c) derived from monoclonal antibodies. Functional disparities among these subclasses are well-documented:
Subclass | Key Functions | Binding to Immune Cells |
---|---|---|
IgG1 | CDCC, ADCC, ADCP; strong complement activation | Monocytes, macrophages, NK cells |
IgG2a | Moderate CDCC/ADCC; efficient complement activation | Similar to IgG1 |
IgG2b | Comparable to IgG1/IgG2a; variable ADCC efficacy | Monocytes, macrophages |
IgG2c | High ADCC/ADCP activity; robust FcγR binding | NK cells, phagocytes |
IgG4 | Complement activation; weaker ADCC than IgG1/IgG2a | Monocytes, macrophages |
IgG3 | Limited Fc-mediated functions; binds monocytes/macrophages weakly | Monocytes, macrophages (weak) |
IgG5b | Poor functional activity; weak FcγR binding | Minimal |
IgG5c | Similar to IgG5b; negligible effector functions | Minimal |
Genomic Organization
Functionally analogous subclasses (e.g., IgG1, IgG2a, IgG2b, IgG2c, IgG4) cluster together in the porcine genome, suggesting evolutionary conservation of effector roles .
The Fc domain governs IgG’s ability to engage immune effectors:
IgG1, IgG2a, IgG2b, IgG2c, and IgG4 mediate ADCC by binding Fcγ receptors on NK cells and neutrophils, triggering cytotoxic granule release. For example, IgG1 exhibits robust ADCC against influenza-infected cells in pig models .
IgG2c and IgG1 promote phagocytosis by opsonizing pathogens, enabling macrophages to engulf and destroy them. IgG2c shows superior ADCP efficiency compared to other subclasses .
IgG1, IgG2a, and IgG2b activate the classical complement pathway, leading to target cell lysis. IgG2a demonstrates higher CDCC efficacy than IgG1 in porcine models .
IgG3 Limitations
IgG3 exhibits minimal Fc-mediated activity except for weak binding to monocytes/macrophages. This contrasts with predictions of high complement activation based on sequence homology, highlighting the need for in vivo validation .
Postnatal changes in N-glycosylation influence IgG’s effector functions. A study analyzing pigs from birth to five months revealed:
Age | N-Glycan Composition (Key Changes) | Functional Implications |
---|---|---|
7–26 days | High GlcNAc (61.4%), low Gal (15.7%) | Maternal IgG (milk-derived); anti-inflammatory |
26–28 days | Increased Man (36.6%) and Gal (23.6%); reduced GlcNAc (39.8%) | Weaning stress; pro-inflammatory shifts |
150 days | Lower Gal, higher GlcNAc; simpler glycans (e.g., Man5GlcNAc2) | Endogenous IgG production; enhanced inflammatory responses |
Developmental Significance
Maternal IgG (via milk) in neonates contains complex, anti-inflammatory glycans, while endogenous IgG in older pigs has simpler, pro-inflammatory structures. This shift aligns with post-weaning immune challenges in swine .
Pigs serve as a large-animal model for testing therapeutic antibodies due to physiological similarities to humans. Porcine IgG1 monoclonal antibodies (e.g., pb27) have demonstrated efficacy in reducing H1N1pdm09 virus shedding and lung pathology .
Blocking Agents: Purified porcine IgG (e.g., Leinco’s AffiPure™) is used to block non-specific binding in flow cytometry and ELISA assays .
ELISA Kits: ALPCO’s porcine IgG ELISA quantifies IgG levels in plasma/serum, aiding in immune monitoring .
IgG subclasses with strong ADCC/CDCC (e.g., IgG1, IgG2c) are candidates for passive immunization strategies against swine pathogens like African swine fever and porcine reproductive and respiratory syndrome (PRRS) .
Porcine IgG subclasses include IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgG4, IgG5b, and IgG5c. These differ significantly in Fc-mediated effector functions:
Subclass | Complement Activation (CDCC) | Antibody-Dependent Cellular Cytotoxicity (ADCC) | Antibody-Dependent Cellular Phagocytosis (ADCP) | Binding to Immune Cells |
---|---|---|---|---|
IgG1 | Strong (Rabbit/Pig complement) | High lytic activity | High phagocytosis | Monocytes, macrophages, NK cells |
IgG2a | Strong | Moderate | Moderate | Monocytes, macrophages, NK cells |
IgG2b | Strong | Moderate | Moderate | Monocytes, macrophages, NK cells |
IgG2c | Strong | High | High | Monocytes, macrophages, NK cells |
IgG3 | None | Weak/no activity | None | Monocytes, macrophages (weak NK binding) |
IgG4 | Strong | High | High | Monocytes, macrophages, NK cells |
IgG5b | None | Weak | Weak | Limited binding |
IgG5c | Weak | Variable | Weak | Limited binding |
Selection for Therapeutic Antibodies: Prioritize IgG1, IgG2a, IgG2b, IgG2c, or IgG4 for Fc-mediated effector functions. IgG3 and IgG5b are functionally limited .
Assay Design: Use cytokine-activated porcine NK cells (e.g., IL-2, IL-12, IL-18) for ADCC/ADCP assays, and rabbit/pig complement for CDCC .
Cytokine-driven polarization of immune responses governs IgG subclass expression:
Cytokine Type | Cytokines Involved | IgG Subclass Bias | Mechanism |
---|---|---|---|
Type 1 | IFN-γ, IL-12 | IgG2 (cell-mediated immunity) | Suppress IgG1 production |
Type 2 | IL-4, IL-10 | IgG1 (antibody-mediated immunity) | Enhance IgG1 secretion |
In Vitro Studies: Culture porcine B cells with recombinant cytokines (e.g., rpIL-10, rpIFN-γ) to analyze IgG1/IgG2 ratios .
In Vivo Models: Use pathogens like Actinobacillus pleuropneumoniae to correlate IgG1:IgG2 ratios with protection .
To identify IgG-binding proteins (e.g., enolase), researchers employ:
Resolve proteins (e.g., enolase, casein) via 12% SDS-PAGE.
Transfer to PVDF membranes and probe with porcine IgG (pIgG) or human IgG (hIgG) at 20 µg/ml.
Detect binding via HRP-conjugated Staphylococcal Protein A (SPA) .
Spot recombinant proteins on PVDF membranes.
Block with 5% skim milk, then incubate with pIgG/hIgG.
Negative Controls: Use casein to exclude non-specific binding .
Validation: Confirm binding regions via N-terminal sequencing or mutagenesis.
Functionally similar subclasses cluster in the genome:
IgG1, IgG2a, IgG2b, IgG2c, IgG4: Grouped in a region associated with strong effector functions.
IgG3, IgG5b, IgG5c: Located in distinct regions with reduced functionality .
Align porcine IGHG genes (e.g., IGHG1: AB699686) to identify homologs.
Use phylogenetic tools (e.g., RAxML) to infer subclass relationships.
Correlate genomic clustering with functional data (e.g., ADCC/CDCC assays) .
Example: IgG3’s role in newborns vs. adults:
In Vitro: No Fc-mediated functions (e.g., CD107a mobilization) .
In Vivo: High IgG3 expression in neonatal gut-associated lymphoid tissues (GALT) suggests pre-adaptive immunity .
Epitope-Specificity: Validate in vivo efficacy with HA-sialic acid-binding antibodies .
Model Systems: Use pig models for influenza to assess therapeutic IgG subclasses (e.g., pb27 IgG1) .
Case Study: For anti-influenza antibodies, prioritize IgG1 for balanced neutralization and effector functions .
Optimizing Fc Functions: Engineer IgG subclasses (e.g., IgG3) to enhance effector activity.
Neonatal Immunity: Investigate IgG3’s role in pre-adaptive responses in piglets.
Cross-Species Therapeutics: Develop porcine mAbs for swine models to avoid anti-human responses .
Genome Editing: CRISPR/Cas9 to modify IGHG loci for subclass switching.
Single-Cell RNA-seq: Profile B-cell responses to pathogens like African swine fever virus.